OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kelly on the Benefit of Immunotherapy in Stage III NSCLC

May 2nd 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).

Dr. Mahipal on Molecular Markers in mCRC

May 2nd 2019

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses emerging molecular markers in patients with metastatic colorectal cancer (mCRC).

Dr. Mason on the Role of Surgery in Stage III NSCLC

May 1st 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses the role of surgery in stage III non–small cell lung cancer.

Dr. Konduri Discusses Promise of NGS Testing in NSCLC

May 1st 2019

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing testing in patients with non–small cell lung cancer.

Dr. Bianchi on Shifting Landscape of Transplant Eligible Myeloma

April 30th 2019

Giada Bianchi, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses treatment options for transplant eligible patients with multiple myeloma.

Dr. Zamarin on Priming Strategies in Ovarian Cancer

April 30th 2019

Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses priming strategies in ovarian cancer.

Dr. Nadler Discusses Role of PD-L1 in Squamous NSCLC

April 29th 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the role of PD-L1 in patients with squamous non–small cell lung cancer.

Dr. Burtness on the Use of Biomarkers in Metastatic HNSCC

April 29th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology) Disease Aligned Research Team Leader, Head and Neck Cancers Program co-director, Developmental Therapeutics Research Program of Yale Cancer Center, discusses the use of biomarkers in metastatic head and neck squamous cell carcinoma.

Dr. Pegram on the Development of Trastuzumab Biosimilars

April 29th 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford's Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women's Cancer Center, discusses the development of trastuzumab biosimilars.

Dr. Sullivan on Immunotherapy Approaches in Melanoma

April 29th 2019

Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses treatment approaches with immunotherapy for patients with melanoma.

Dr. Backes on Sentinel Lymph Node Mapping in Cervical Cancer

April 29th 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, at The Ohio State University Comprehensive Cancer Center, discusses the use of sentinel lymph node mapping in patients with cervical cancer.

Dr. Nadeem on Sequencing Considerations in Multiple Myeloma

April 29th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses sequencing challenges in multiple myeloma.

Updated Screening Guidelines in Prostate Cancer

April 27th 2019

MaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, American Cancer Society, discusses updated screening guidelines in prostate cancer.

Dr. Chung on a Joint Analysis of Immunotherapy Trials in SCLC

April 27th 2019

Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).

Impact of Genetic Variant on Stroke Risk in Childhood Cancer Survivors Treated With Cranial Radiation Therapy

April 27th 2019

Yadav Sapkota, PhD, clinical research scientist at St. Jude Children’s Research Hospital, discusses the relationship between a genetic variant and the risk of stroke in childhood cancer survivors treated with cranial radiation therapy.

Dr. Randall on Emerging Treatment Strategies in Cervical Cancer

April 26th 2019

Leslie M. Randall, MD, associate professor, Division of Gynecologic Oncology, UC Irvine Health, discusses emerging treatment strategies in the treatment of patients with cervical cancer.

Dr. Kim on the Potential of Ramucirumab in Advanced HCC

April 26th 2019

Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.

Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC

April 26th 2019

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

Dr. Mullighan on Germline Predisposition to ALL

April 26th 2019

Charles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).

Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer

April 26th 2019

Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.